{"id":1201,"company":{"country":"CH","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2016-10-19","marketCap":5599.19287109375,"name":"CRISPR Therapeutics AG","phone":"41415613279.0","outstanding":79.41000366210938,"symbol":"CRSP","website":"https://crisprtx.com/","industry":"Biotechnology"},"price":70.2775,"year":2023,"month":11,"day":23,"weekday":"Thursday","title":"Impact of recent mergers and acquisitions on CRISPR Therapeutics AG stock and its competitors","date":"2023-11-23","url":"/posts/2023/11/23/CRSP","content":[{"section":"Introduction","text":"The CRISPR Therapeutics industry, which focuses on developing gene-editing technologies, has been witnessing increasing merger and acquisition (M\u0026A) activities in recent years. These M\u0026A deals have had a profound impact on the stock of CRISPR Therapeutics AG and its competitors. Moreover, the industry has experienced significant consolidation, which has reshaped the competitive landscape and potentially affected the future growth prospects of various companies."},{"section":"Effect on CRISPR Therapeutics AG stock","text":"Mergers and acquisitions involving CRISPR Therapeutics AG have influenced the stock's performance. Positive M\u0026A deals, such as strategic partnerships, acquisitions of complementary technologies, or licensing agreements, have generally resulted in increased investor confidence and a surge in stock prices. On the other hand, unfavorable M\u0026A deals or failed negotiations have led to decreased stock prices and investor skepticism."},{"section":"Competitors' response","text":"The M\u0026A activities in the CRISPR Therapeutics industry have also triggered a ripple effect among its competitors. Companies operating in the same space as CRISPR Therapeutics AG have actively engaged in mergers, acquisitions, and collaborations to strengthen their own positions, acquire new technologies, or expand their product portfolios. These moves have aimed at retaining competitiveness and capitalizing on the growing demand for gene-editing technologies."},{"section":"Industry consolidation","text":"The recent mergers and acquisitions have led to significant industry consolidation. Larger pharmaceutical companies, eager to tap into the potential of CRISPR gene-editing, have acquired smaller players in the CRISPR Therapeutics market. This consolidation has resulted in the concentration of technology, expertise, and intellectual property within a few major entities. Consequently, smaller companies without the financial resources or competitive advantage may face increased challenges in competing with these established players."},{"section":"Future implications","text":"The ongoing consolidation within the CRISPR Therapeutics industry may have both positive and negative implications. On the positive side, larger companies with enhanced resources and capabilities can potentially accelerate the development and commercialization of gene-editing therapies, benefiting patients and shareholders. However, the concentration of power and limited competition could hinder innovation and lead to potential monopolistic practices. Additionally, smaller companies might struggle to secure funding and find it challenging to establish a presence in the market."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1700658420,"headline":"5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright","id":124050233,"image":"https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","symbol":"CRSP","publisher":"Yahoo","summary":"New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.","url":"https://finance.yahoo.com/news/5-biotech-stocks-likely-thrive-130700389.html"},{"category":"company","date":1700656200,"headline":"Is CRISPR Therapeutics the Best Gene-Editing Stock?","id":124051705,"image":"https://s.yimg.com/ny/api/res/1.2/J78WaI4HO.EcqYEmqHv6_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/36d4305e77224f007ea45892190b4dcb","symbol":"CRSP","publisher":"Yahoo","summary":"A striking analogy can be drawn between the development of monoclonal antibodies and the emergence of CRISPR-based gene editing.  Since the first Food and Drug Administration (FDA) approval of a monoclonal antibody in 1986, the field has expanded rapidly, and several of the top-selling therapies of all time have originated from this technology.  If CRISPR gene editing follows a similar trajectory, early shareholders in companies that develop the groundbreaking tech ought to reap huge rewards in the coming decades.","url":"https://finance.yahoo.com/m/91b811a0-b88f-3855-a488-a8cb1c29f355/is-crispr-therapeutics-the.html"},{"category":"company","date":1700649000,"headline":"3 Biotech Stocks That Could Be Millionaire Makers","id":124048098,"image":"https://s.yimg.com/ny/api/res/1.2/bSEkmQJq6OMfaN6H7IGUdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/f01c078ce1b7c7e26adbd9e1bb2ddfdb","symbol":"CRSP","publisher":"Yahoo","summary":"In my view, these three players, held as part of a diversified portfolio, could be millionaire makers.  CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge moment in its story as a company.  Along with partner Vertex Pharmaceuticals, it earned the world's first authorization for a gene-editing treatment that uses the \"CRISPR technique.\"","url":"https://finance.yahoo.com/m/b0cd811f-33b5-3ec4-8023-e42c2af074f1/3-biotech-stocks-that-could.html"},{"category":"company","date":1700571626,"headline":"These Stocks Are Exploding In The November Stock Market Rally","id":124015770,"image":"https://media.zenfs.com/en/ibd.com/76a0dec4e6ee6054993fd61e199c6a00","symbol":"CRSP","publisher":"Yahoo","summary":"The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.","url":"https://finance.yahoo.com/m/57cc545f-630a-35ff-9662-3d5274fcf035/these-stocks-are-exploding-in.html"},{"category":"company","date":1700564940,"headline":"CRSP September 2024 Options Begin Trading","id":124033107,"image":"","symbol":"CRSP","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3222856879"},{"category":"company","date":1700535960,"headline":"Market Today: Tech Giants and Biotech Suffer Amid Market Retreat","id":124032132,"image":"","symbol":"CRSP","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3223168273"},{"category":"company","date":1700532900,"headline":"Gene editing stocks slide after two-day rally","id":124028649,"image":"","symbol":"CRSP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3223099263"},{"category":"company","date":1700492120,"headline":"Wall Street Analysts Believe CRISPR Therapeutics AG (CRSP) Could Rally 33.75%: Here's is How to Trade","id":124012541,"image":"https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4","symbol":"CRSP","publisher":"Yahoo","summary":"The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.","url":"https://finance.yahoo.com/news/wall-street-analysts-believe-crispr-145520905.html"},{"category":"company","date":1700483820,"headline":"Crispr Therapeutics AG’s Historic Milestone: Regulatory Approval for Gene-Editing Therapy Boosts Stock Buy Rating","id":124007481,"image":"","symbol":"CRSP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3220678383"},{"category":"company","date":1700474100,"headline":"Biotech Alert: Searches spiking for these stocks today","id":123996986,"image":"","symbol":"CRSP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3221109835"},{"category":"company","date":1700473500,"headline":"Crispr Therapeutics call volume above normal and directionally bullish","id":124007483,"image":"","symbol":"CRSP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3221099516"},{"category":"company","date":1700466540,"headline":"Google’s Bard AI Says These 3 Stocks Will Rise 1,000%","id":123995167,"image":"","symbol":"CRSP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3220976521"},{"category":"company","date":1700445060,"headline":"Are You A Trader Or Investor: Biotech Momentum Is Picking Up","id":124003035,"image":"","symbol":"CRSP","publisher":"TalkMarkets","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3221393915"},{"category":"company","date":1700389800,"headline":"Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?","id":123979579,"image":"https://s.yimg.com/ny/api/res/1.2/CqoQc0oq.88njOk2W93UnQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/a2407fdf1273d39d3ed27feff0ed7d21","symbol":"CRSP","publisher":"Yahoo","summary":"All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment.  CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting regulatory decisions on exa-cel, their candidate to treat blood disorders sickle cell disease and beta thalassemia.  This makes it the world's first authorization for a gene editing treatment using CRISPR technology.","url":"https://finance.yahoo.com/m/8ec6f46a-95b2-3e6d-b3f4-484f73ac9450/could-investing-%2410%2C000-in.html"},{"category":"company","date":1700308140,"headline":"3 Monster Stocks in the Making","id":123970770,"image":"https://s.yimg.com/ny/api/res/1.2/kj1k0ThsQiviQmIBVTAh9g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/45ddfdee39ce074b7aad084b5c8260da","symbol":"CRSP","publisher":"Yahoo","summary":"Here's why three Motley Fool contributors think Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), and Sarepta Therapeutics (NASDAQ: SRPT) have what it takes.  Keith Speights (Beam Therapeutics): Some technologies simply have the \"it factor.\"  Base editing is a type of gene editing.","url":"https://finance.yahoo.com/m/a2699426-2cc6-3f01-865d-025eb2c6b89a/3-monster-stocks-in-the-making.html"},{"category":"company","date":1700237535,"headline":"Why CRISPR Therapeutics Stock Is Jumping Again Today","id":123965835,"image":"https://s.yimg.com/ny/api/res/1.2/kkwZnbnZrgEssYUHlBb1hg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0ae1ad108f9ea7ce35812c394098046a","symbol":"CRSP","publisher":"Yahoo","summary":"Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%. There's a good reason for this accelerated momentum for the gene-editing stock.","url":"https://finance.yahoo.com/m/8b301680-b0c9-30d0-8966-93c9a55dff6b/why-crispr-therapeutics-stock.html"},{"category":"company","date":1700236860,"headline":"CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News","id":123965836,"image":"https://media.zenfs.com/en/ibd.com/3417047a4b024123b3a81ee1e1f53d5e","symbol":"CRSP","publisher":"Yahoo","summary":"When looking for the best stocks to buy and watch, focus on those with rising relative price strength.  One stock that fits that bill is CRISPR Therapeutics, which had its Relative Strength (RS) Rating upgraded from 78 to 88 Friday.  See Allison Gatlin's full report on the news reported yesterday.","url":"https://finance.yahoo.com/m/2703151d-284d-3df5-becc-0d2969b331c3/crispr-therapeutics-stock.html"},{"category":"company","date":1700226900,"headline":"Cutting-Edge Crispr Therapeutics Has Made a Long Base: Time to Get Onboard?","id":123965837,"image":"https://media.zenfs.com/en/thestreet.com/549490513accf96aa6f310513fac38d3","symbol":"CRSP","publisher":"Yahoo","summary":"Crispr Therapeutics  develops transformative gene-based medicines for serious human diseases.  In the daily bar chart of CRSP, below, I can see some recent improvement in the chart and with the indicators.  The trading volume has really increased in the past 2 1/2 months.","url":"https://finance.yahoo.com/m/a028b61b-c441-33b3-a8c8-dce849017245/cutting-edge-crispr.html"},{"category":"company","date":1700218800,"headline":"The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics","id":123945070,"image":"https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c","symbol":"CRSP","publisher":"Yahoo","summary":"Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.","url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-arcellx-110000380.html"},{"category":"company","date":1700217360,"headline":"Interesting CRSP Put And Call Options For July 2024","id":123954336,"image":"","symbol":"CRSP","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3217679726"},{"category":"company","date":1700215560,"headline":"Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday","id":123949259,"image":"","symbol":"CRSP","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3217644110"},{"category":"company","date":1700168788,"headline":"Market Today: CRISPR Therapeutics and Vertex Pharmaceuticals Make History with UK Drug Approval","id":123935698,"image":"https://media.zenfs.com/en/us.finance.gurufocus/6311034f5afebc96247e2511f0d68595","symbol":"CRSP","publisher":"Yahoo","summary":"Summary of market news for Nov. 16","url":"https://finance.yahoo.com/news/market-today-crispr-therapeutics-vertex-210628515.html"},{"category":"company","date":1700158020,"headline":"U.K. Approves First ‘Genetic Scissors’ Treatment","id":123927486,"image":"","symbol":"CRSP","publisher":"Yahoo","summary":"A Nobel Prize-winning gene editing therapy has been conditionally approved in the U.K., as U.S. regulators near decision.","url":"https://finance.yahoo.com/m/1eee8d56-b3d6-3e0e-945f-c3ba25db47ea/u.k.-approves-first-%E2%80%98genetic.html"},{"category":"company","date":1700153220,"headline":"CRISPR (CRSP), Vertex Get UK Nod for First Gene Therapy Casgevy","id":123927487,"image":"https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629","symbol":"CRSP","publisher":"Yahoo","summary":"CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.","url":"https://finance.yahoo.com/news/crispr-crsp-vertex-uk-nod-164700521.html"},{"category":"company","date":1700148600,"headline":"Biotech Stock Roundup: BMY's Drug Approval, VRTX \u0026 CRSP Gene Therapy Get MHRA Nod","id":123926119,"image":"https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","symbol":"CRSP","publisher":"Yahoo","summary":"Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.","url":"https://finance.yahoo.com/news/biotech-stock-roundup-bmys-drug-153000572.html"},{"category":"company","date":1700144860,"headline":"Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug","id":123918486,"image":"","symbol":"CRSP","publisher":"Yahoo","summary":"In a world first, regulators in the UK approved Crispr's gene-editing treatment for two blood diseases on Thursday, and CRSP stock surged.","url":"https://finance.yahoo.com/m/4ce79342-7898-39b9-9cba-3697eeac8c6e/crispr-surges-after-winning.html"},{"category":"company","date":1700144453,"headline":"Morning Brew: Walmart Slips on Forecast, Alibaba (BABA) faced an 8% drop after its ...","id":123918867,"image":"https://media.zenfs.com/en/us.finance.gurufocus/4d6aff6d32d70fdc3b3d34c67bed9c21","symbol":"CRSP","publisher":"Yahoo","summary":"Walmart Slips on Forecast, Alibaba (BABA) faced an 8% drop after its second-quarter revenue missed estimates","url":"https://finance.yahoo.com/news/morning-brew-walmart-slips-forecast-142053422.html"},{"category":"company","date":1700136900,"headline":"World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia","id":123927492,"image":"https://www.biopharmadive.com/imgproxy/-Ie9-WWMdOmKvn3sbO2NvHUkh8OH5pFOLPPbZPEImOI/g:ce/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTk2ODA1OTkzNi5qcGc.jpg","symbol":"CRSP","publisher":"Yahoo","summary":"Clearance of Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy in the U.K. comes ahead of expected regulatory decisions in the U.S. and Europe.","url":"https://www.biopharmadive.com/news/crispr-first-approval-uk-vertex-sickle-cell-casgevy/700020/"},{"category":"company","date":1700136036,"headline":"The world's first gene therapy for sickle cell disease has been approved in Britain","id":123922607,"image":"","symbol":"CRSP","publisher":"Finnhub","summary":"LONDON — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the...","url":"https://finnhub.io/api/news?id=dc90fc7934b17ff459dda5b023e37df5e5a36e4cd58eed761f17d4a6831940f7"},{"category":"company","date":1700130840,"headline":"Crispr Therapeutics (NASDAQ:CRSP) Notches Up on World-First Therapy","id":123934171,"image":"","symbol":"CRSP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215868731"},{"category":"company","date":1700130600,"headline":"Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.","id":123921738,"image":"https://s.yimg.com/ny/api/res/1.2/jCuk0bRT1MYTEy.YTAT0NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTg-/https://media.zenfs.com/en/motleyfool.com/bdef3769196cccb301553b7a02eee4b6","symbol":"CRSP","publisher":"Yahoo","summary":"CRISPR Therapeutics (NASDAQ: CRSP) has reached a very exciting point in its story.  The biotech company that specializes in gene editing is awaiting regulatory decisions on what could become its first commercialized product.  The U.S. Food and Drug Administration (FDA) is set to rule on exa-cel for sickle cell disease next month and exa-cel for beta thalassemia in March.","url":"https://finance.yahoo.com/m/5d457638-47b5-3db6-a3e1-40f7e3fa2b95/can-crispr-therapeutics-stock.html"},{"category":"company","date":1700129359,"headline":"The world's first gene therapy for sickle cell and thalassemia has been approved","id":123918921,"image":"","symbol":"CRSP","publisher":"Finnhub","summary":"LONDON — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the...","url":"https://finnhub.io/api/news?id=955506c8bd1f997747c08f02d2b3363924ff5dc8139c92d0d5d949db67e903d2"},{"category":"company","date":1700129048,"headline":"In a world first, the UK approves gene therapy for sickle cell and thalassemia","id":123918870,"image":"","symbol":"CRSP","publisher":"Finnhub","summary":"LONDON — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the...","url":"https://finnhub.io/api/news?id=83f76d4abd8e3b4a522404c51f2a659f429848d7242ca8072e5164e15a66da98"},{"category":"company","date":1700124540,"headline":"Crispr Therapeutics, Vertex get world's first regulatory green light for CRISPR-based medicine","id":123961089,"image":"https://images.mktw.net/im-512397/social","symbol":"CRSP","publisher":"MarketWatch","summary":"Shares of Crispr Therapeutics, Vertex gain ground after first regulatory clearance for medicine based on transformative gene-editing technology","url":"https://www.marketwatch.com/story/crispr-therapeutics-vertex-get-worlds-first-regulatory-green-light-for-crispr-based-medicine-c051bb14"},{"category":"company","date":1700124420,"headline":"Why Is NIO Stock Down 5% Today?","id":123924249,"image":"","symbol":"CRSP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215727146"},{"category":"company","date":1700123880,"headline":"Buy Rating Assigned to Crispr Therapeutics AG Following Approval of First CRISPR-Engineered Product","id":123934173,"image":"","symbol":"CRSP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215715728"},{"category":"company","date":1700123636,"headline":"Gene therapy for sickle cell and thalassemia gets approval in the UK, a world first","id":123917274,"image":"","symbol":"CRSP","publisher":"Finnhub","summary":"LONDON — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the...","url":"https://finnhub.io/api/news?id=459dcff779b76e4920bc9fd89dace19eeaf3e35d7774f6f58e7735fc815b9f0b"},{"category":"company","date":1700123117,"headline":"UK authorises gene therapy for blood disorders in world first","id":123914573,"image":"","symbol":"CRSP","publisher":"Reuters","summary":"Britain has authorised a gene therapy that aims to cure sickle-cell disease and another type of inherited blood disorder for patients aged 12 and over, the country's medical regulator said on Thursday, becoming the first in the world to do so.","url":"https://www.reuters.com/article/vertex-pharms-crispr-therapeut-britain/uk-authorises-gene-therapy-for-blood-disorders-in-world-first-idUSKBN32B0ID"},{"category":"company","date":1700122800,"headline":"Citi Is Souring on Plug Power (PLUG) Stock","id":123922067,"image":"","symbol":"CRSP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215692647"},{"category":"company","date":1700121600,"headline":"Biggest stock movers today: Alibaba, Walmart, Cisco Systems, Palo Alto Networks and more","id":123920135,"image":"","symbol":"CRSP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215667464"},{"category":"company","date":1700121360,"headline":"Buy Rating for Crispr Therapeutics AG Following World’s First Approval of a CRISPR-Based Therapy","id":123934176,"image":"","symbol":"CRSP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215663141"},{"category":"company","date":1700121060,"headline":"Crispr Therapeutics, Vertex get world’s first regulatory green light for CRISPR-based medicine","id":123934178,"image":"","symbol":"CRSP","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215657017"},{"category":"company","date":1700120880,"headline":"CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy","id":123934179,"image":"","symbol":"CRSP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215653875"},{"category":"company","date":1700119140,"headline":"UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia","id":123934180,"image":"","symbol":"CRSP","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215621128"},{"category":"company","date":1700118780,"headline":"Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket","id":123922074,"image":"","symbol":"CRSP","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215613406"},{"category":"company","date":1700117100,"headline":"Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia","id":123913235,"image":"https://media.zenfs.com/en/business-wire.com/ee81ebc3f0bf9a66aad8452da6e50c0e","symbol":"CRSP","publisher":"Yahoo","summary":"BOSTON \u0026 ZUG, Switzerland, November 16, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).","url":"https://finance.yahoo.com/news/vertex-crispr-therapeutics-announce-authorization-064500132.html"},{"category":"company","date":1700114163,"headline":"UK becomes 1st country to approve gene therapy treatment for sickle cell, thalassemia","id":123915498,"image":"","symbol":"CRSP","publisher":"Finnhub","summary":"LONDON — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the...","url":"https://finnhub.io/api/news?id=64f88d01ab9b21074344c585277106d6c5fd34fc38a1553028d197e72f6f54e3"},{"category":"company","date":1700112900,"headline":"Vertex and Crispr get UK green light for gene-edited therapy","id":123934182,"image":"","symbol":"CRSP","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=bwfzgatcpw"},{"category":"company","date":1700109960,"headline":"UK approves world-first sickle cell gene-editing therapy from Vertex-Crispr","id":123934183,"image":"","symbol":"CRSP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215473957"},{"category":"company","date":1700109420,"headline":"Vertex Pharmaceuticals, Crispr Therapeutics get MHRA authorization for Casgevy","id":123934184,"image":"","symbol":"CRSP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215466153"},{"category":"company","date":1700109240,"headline":"Biggest stock movers today: Cisco Systems, Palo Alto Networks and more","id":123920160,"image":"","symbol":"CRSP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3215463778"},{"category":"company","date":1700103300,"headline":"Gene editing stocks mixed despite world’s first CRISPR drug approval","id":123934187,"image":"","symbol":"CRSP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3216244706"},{"category":"company","date":1700101800,"headline":"3 Long-Term Growth Stocks Analysts Are Bullish On","id":123932982,"image":"","symbol":"CRSP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3216206096"},{"category":"company","date":1700100780,"headline":"3 Cathie Wood You’ll Regret Not Buying Soon: November 2023","id":123934189,"image":"","symbol":"CRSP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3216180512"},{"category":"company","date":1700074533,"headline":"Invest in the Future With These 7 Forever Stocks","id":124027808,"image":"https://media.zenfs.com/en/investorplace_417/f24c461e0b99f1a1a2c7da10eb73c68d","symbol":"CRSP","publisher":"Yahoo","summary":"One of my favorite investment strategies when seeking forever stocks is to look to past trends that turned stale. Think of some of the hottest sectors in the past five years that saw massive investor interest before falling back to Earth. Cannabis stocks, pandemic stocks, streaming stocks, even electric vehicle (EV) stocks. All had their heyday, buffeted by a record bull run, but collectively traded at a fraction of their past pricing. The trick is to identify past winners in an emerging sector","url":"https://finance.yahoo.com/news/invest-future-7-forever-stocks-185533998.html"},{"category":"company","date":1700072779,"headline":"3 Biotech Stocks With Key Catalysts Coming in December","id":124028528,"image":"https://media.zenfs.com/en/investorplace_417/03737c9cbe7ca910ba80c3b95d561df1","symbol":"CRSP","publisher":"Yahoo","summary":"Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money. Look at CRISPR Therapeutics (NASDAQ:CRSP), for example. On Oct. 31, the company announced a US FDA advisory committee green-lighted its gene editing therapy for the treatment of severe sickle cell disease. On that news, CRSP jumped from about $38.93 to a high of $57.50. But it’s run isn’t over just yet. In fact, CRSP is","url":"https://finance.yahoo.com/news/3-biotech-stocks-key-catalysts-182619226.html"},{"category":"company","date":1700045280,"headline":"Cathie Wood’s ARK Innovation Is on a Tear, With ‘Supercharged Tech Returns’","id":123961256,"image":"https://images.barrons.com/im-92265618/social","symbol":"CRSP","publisher":"MarketWatch","summary":"Since Oct. 27, the flagship ETF has returned more than double the S\u0026P 500's gain.","url":"https://www.marketwatch.com/articles/cathie-wood-ark-innovation-etf-tech-stocks-3fe26e7b"},{"category":"company","date":1699956000,"headline":"2 Stocks to Buy Hand Over Fist as the S\u0026P 500 Rockets Higher","id":123858245,"image":"https://s.yimg.com/ny/api/res/1.2/NovkUwkgWbgn.Ic6O9zGSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/89f9e073a5c2cecf44345de9dc7e5094","symbol":"CRSP","publisher":"Yahoo","summary":"The S\u0026P 500 posted its best week of the year earlier this month, gaining more than 5%, and the index extended the gain last week with an increase of more than 1%.  It's impossible to predict whether the rally will last and lead to a bull market -- or if we'll have to wait a bit longer for indexes to move into that high-growth phase.  Amazon is a leader in two markets growing in the double digits: e-commerce and cloud computing.","url":"https://finance.yahoo.com/m/8a093270-d9d5-3d84-90d1-1f3033f77937/2-stocks-to-buy-hand-over.html"},{"category":"company","date":1699795115,"headline":"3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024","id":123970711,"image":"https://media.zenfs.com/en/investorplace_417/e14ff989edc95ee2d23d9ab566afe6d7","symbol":"CRSP","publisher":"Yahoo","summary":"When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical trials, as companies with early stage drugs are too risky for me. Unfortunately, a high percentage of drugs that have not yet undergone clinical trials or are in early-stage clinical trials end up failing. As a result, I avoid the shares of companies whose only drugs are in these stages. On the other hand","url":"https://finance.yahoo.com/news/3-biotech-stocks-poised-breakthroughs-131835561.html"},{"category":"company","date":1699709400,"headline":"1 No-Brainer Stock to Buy and Hold for 10 Years","id":123811949,"image":"","symbol":"CRSP","publisher":"Yahoo","summary":"Investing in healthcare stocks has its perks.  Plenty of corporations on the market can do so, one of which is CRISPR Therapeutics (NASDAQ: CRSP).  Gene editing is a set of techniques that allows scientists to make precise changes to an organism's DNA.","url":"https://finance.yahoo.com/m/f611f513-849d-3ef3-81ad-ef82929185ce/1-no-brainer-stock-to-buy-and.html"},{"category":"company","date":1699635048,"headline":"Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision","id":123795731,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441074609/image_1441074609.jpg?io=getty-c-w1536","symbol":"CRSP","publisher":"SeekingAlpha","summary":"Beam Therapeutics' slow progress and setbacks in gene editing technology raise doubts about its valuation and competitive position. Learn more on BEAM stock here.","url":"https://seekingalpha.com/article/4650531-beam-therapeutics-sale-of-rights-to-verves-in-vivo-candidates-an-odd-decision"},{"category":"company","date":1699562226,"headline":"3 Biotech Stocks That Are Betting on the Future of Gene Editing","id":123903330,"image":"https://media.zenfs.com/en/investorplace_417/b912a2b47d4b301fa5481b7d77ee6c13","symbol":"CRSP","publisher":"Yahoo","summary":"The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed. But even before then, the roadmap gave researchers the opportunity to develop gene therapies to correct genetic abnormalities. Gene editing, which seeks to directly alter a patient’s genome itself, is the next stage. If successful, it may provide a viable treatment for many previously untreatable genetic disorders. That is why","url":"https://finance.yahoo.com/news/3-biotech-stocks-betting-future-203706899.html"}]}